Safety and immunogenicity of influenza vaccine among HIV-infected adults: Conventional vaccine vs. intradermal vaccine

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 2, 2016, Pages 478-484

  Seo, Yu Bin ^a   Lee, Jacob ^a   Song, Joon Young ^b   Choi, Hee Jung ^c   Cheong, Hee Jin ^b   Kim, Woo Joo ^b  

^a Hallym University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c Ewha Womans University School of Medicine   (South Korea)

Author keywords

HIV; immunogenicity; influenza vaccine; intradermal vaccine; safety

Indexed keywords

GAMMA INTERFERON; HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INACTIVATED VACCINE;

ADULT; ARTICLE; DRUG ADMINISTRATION ROUTE; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEROCONVERSION; SKIN REDNESS; VACCINATION; ADOLESCENT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED STUDY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; IMMUNOLOGY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA B VIRUS; INTRADERMAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; LYMPHOCYTE COUNT; MIDDLE AGED; VACCINE IMMUNOGENICITY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HUMANS; IMMUNOGENICITY, VACCINE; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA B VIRUS; INFLUENZA VACCINES; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; VACCINES, INACTIVATED; VIRAL LOAD; YOUNG ADULT;

EID: 84960965617     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2015.1076599     Document Type: Article

References (25)

1. K.M.Neuzil, C.S.Coffey, E.F.Mitchel, Jr., M.R.Griffin. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr 2003; 34:304-7; PMID:14600576; http://dx.doi.org/10.1097/00126334-200311010-00008
2. J.C.Lin, K.L.Nichol. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161:441-6; PMID:11176770; http://dx.doi.org/10.1001/archinte.161.3.441
3. L.A.Pinto, V.Blazevic, S.A.Anderson, D.J.Venzon, C.M.Trubey, T.Rowe, J.M.Katz, D.Liewehr, M.J.Dolan, G.M.Shearer. Influenza virus-stimulated generation of anti-human immunodeficiency virus (HIV) activity after influenza vaccination in HIV-infected individuals and healthy control subjects. J Infect Dis 2001; 183:1000-8; PMID:11237823; http://dx.doi.org/10.1086/319277
4. M.Santini-Oliveira, L.A.Camacho, T.M.Souza, P.M.Luz, M.T.Vasconcellos, C.B.Giacoia-Gripp, M.G.Morgado, E.P.Nunes, A.S.Lemos, A.C.Ferreira, et al. H1N1pdm09 adjuvanted vaccination in HIV-infected adults: a randomized trial of two single versus two double doses. PloS one 2012; 7:e39310; PMID:22761759; http://dx.doi.org/10.1371/journal.pone.0039310.
5. N.F.Crum-Cianflone, L.E.Eberly, C.Duplessis, J.Maguire, A.Ganesan, D.Faix, G.Defang, Y.Bai, E.Iverson, T.Lalani, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine in an immunocompromised population: a prospective study comparing HIV-infected adults with HIV-uninfected adults. Clin Infect Dis 2011; 52:138-46; PMID:21148532; http://dx.doi.org/10.1093/cid/ciq019.
6. P.G.Miotti, K.E.Nelson, G.A.Dallabetta, H.Farzadegan, J.Margolick, M.L.Clements. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989; 262:779-83; http://dx.doi.org/10.1001/jama.1989.03430060075029.
7. K.E.Nelson, M.L.Clements, P.Miotti, S.Cohn, B.F.Polk. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988; 109:383-8; PMID:2970238; http://dx.doi.org/10.7326/0003-4819-109-5-383.
8. A.Malaspina, S.Moir, S.M.Orsega, J.Vasquez, N.J.Miller, E.T.Donoghue, S.Kottilil, M.Gezmu, D.Follmann, G.M.Vodeiko, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005; 191:1442-50; PMID:15809902; http://dx.doi.org/10.1086/429298.
9. M.B.Klein, Y.Lu, L.DelBalso, S.Cote, G.Boivin. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007; 45:234-40; PMID:17578785; http://dx.doi.org/10.1086/518986.
10. F.Young, F.Marra. A systematic review of intradermal influenza vaccines. Vaccine 2011; 29:8788-801; PMID:21968444; http://dx.doi.org/10.1016/j.vaccine.2011.09.077.
11. R.T.Kenney, S.A.Frech, L.R.Muenz, C.P.Villar, G.M.Glenn. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004; 351:2295-301; PMID:15525714; http://dx.doi.org/10.1056/NEJMoa043540.
12. P.Durando, D.Fenoglio, A.Boschini, F.Ansaldi, G.Icardi, L.Sticchi, A.Renzoni, P.Fabbri, A.Ferrera, A.Parodi, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008; 15:253-9; PMID:18003811; http://dx.doi.org/10.1128/CVI.00316-07.
13. G.Gabutti, M.Guido, P.Durando, A.De Donno, M.Quattrocchi, S.Bacilieri, F.Ansaldi, S.Cataldini, P.G.Chiriac∫, M.De Simone, et al. Safety and immunogenicity of conventional subunit and MF59-adjuvanted influenza vaccines in human immunodeficiency virus-1-seropositive patients. J Int Med Res 2005; 33:406-16; PMID:16104444; http://dx.doi.org/10.1177/147323000503300406.
14. N.McKittrick, I.Frank, J.M.Jacobson, C.J.White, D.Kim, R.Kappes, C.DiGiorgio, T.Kenney, J.Boyer, P.Tebas. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons: a single-center, parallel, randomized trial. Ann Intern Med 2013; 158:19-26; PMID:23277897; http://dx.doi.org/10.7326/0003-4819-158-1-201301010-00005.
15. C.Cooper, A.Thorne, M.Klein, B.Conway, G.Boivin, D.Haase, S.Shafran, W.Zubyk, J.Singer, S.Halperin, et al. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV infected adults. PloS One 2011; 6:e17758; PMID:21512577; http://dx.doi.org/10.1371/journal.pone.0017758.
16. K.Palucka, J.Banchereau, I.Mellman. Designing vaccines based on biology of human dendritic cell subsets. Immunity 2010; 33:464-78; PMID:21029958; http://dx.doi.org/10.1016/j.immuni.2010.10.007.
17. F.Ansaldi, L.Valle, D.de Florentiis, V.Parodi, G.Murdaca, B.Bruzzone, P.Durando, M.Setti, G.Icardi. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults. Hum Vaccin Immunother 2012; 8:1048-52; PMID:22832261; http://dx.doi.org/10.4161/hv.20347.
18. S.B.Troy, D.Kouiavskaia, J.Siik, E.Kochba, H.Beydoun, O.Mirochnitchenko, Y.Levin, N.Khardori, K.Chumakov, Y.Maldonado. Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-infected adults. J Infect Dis 2015; 211:1969-76; PMID:25567841; http://dx.doi.org/10.1093/infdis/jiu841.
19. S.A.Madhi, M.Maskew, A.Koen, L.Kuwanda, T.G.Besselaar, D.Naidoo, C.Cohen, M.Valette, C.L.Cutland, I.Sanne. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis 2011; 52:128-37; PMID:21148531; http://dx.doi.org/10.1093/cid/ciq004.
20. M.M.Schneider, M.J.Sprenger, I.M.Hoepelman, Y.van der Graaf, J.C.Borleffs. Antibody response to tetravalent influenza subunit vaccine in patients infected with human immunodeficiency virus type 1. Int J Antimicrob Agents 1996; 6:195-200; PMID:18611709; http://dx.doi.org/10.1016/0924-8579(95)00038-0.
21. F.P.Kroon, J.T.van Dissel, J.C.de Jong, R.van Furth. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. Aids 1994; 8:469-76; PMID:7912086; http://dx.doi.org/10.1097/00002030-199404000-00008.
22. C.L.Cooper. Pandemic H1N12009 influenza and HIV: a review of natural history, management and vaccine immunogenicity. Curr Opin Infect Dis 2012; 25:26-35; PMID:22183114; http://dx.doi.org/10.1097/QCO.0b013e32834ef56c.
23. F.P.Kroon, J.T.van Dissel, J.C.de Jong, K.Zwinderman, R.van Furth. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18:3040-9; PMID:10825608; http://dx.doi.org/10.1016/S0264-410X(00)00079-7.
24. N.Kishida, S.Fujisaki, M.Yokoyama, H.Sato, R.Saito, H.Ikematsu, H.Xu, E.Takashita, M.Tashiro, S.Takao, et al. Evaluation of influenza virus A/H3N2 and B vaccines on the basis of cross-reactivity of postvaccination human serum antibodies against influenza viruses A/H3N2 and B isolated in MDCK cells and embryonated hen eggs. Clin Vaccine Immunol 2012; 19:897-908; PMID:22492743; http://dx.doi.org/10.1128/CVI.05726-11.
25. H.J.Cheong, J.Y.Song, J.W.Park, J.E.Yeon, K.S.Byun, C.H.Lee, H.I.Cho, T.G.Kim, W.J.Kim. Humoral and cellular immune responses to influenza vaccine in patients with advanced cirrhosis. Vaccine 2006; 24:2417-22; PMID:16406176; http://dx.doi.org/10.1016/j.vaccine.2005.11.064.